Sarepta Therapeutics (SRPT) Tops Q2 EPS by 92c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), $0.92 better than the analyst estimate of ($1.77). Revenue for the quarter came in at $261.2 million versus the consensus estimate of $259.79 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Ennis (EBF) Reports In-Line Q1 EPS